WallStSmart

Alpha Tau Medical Ltd (DRTS)vsBeiGene, Ltd. (ONC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ONC leads profitability with a 8.9% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 54/100 (C-).

DRTS

Avoid

17

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -1.47

ONC

Buy

54

out of 100

Grade: C-

Growth: 10.0Profit: 6.5Value: 5.7Quality: 7.0
Piotroski: 5/9Altman Z: 0.75
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DRTS.

ONCUndervalued (+81.1%)

Margin of Safety

+81.1%

Fair Value

$1857.02

Current Price

$322.08

$1534.94 discount

UndervaluedFair: $1857.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DRTS1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

ONC3 strengths · Avg: 9.7/10
Revenue GrowthGrowth
35.5%10/10

Revenue surging 35.5% year-over-year

EPS GrowthGrowth
16971.0%10/10

Earnings expanding 16971.0% YoY

Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Areas to Watch

DRTS4 concerns · Avg: 3.8/10
Price/BookValuation
15.4x4/10

Trading at 15.4x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.20B3/10

Smaller company, higher risk/reward

ONC2 concerns · Avg: 2.0/10
P/E RatioValuation
74.6x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.752/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : DRTS

The strongest argument for DRTS centers on Debt/Equity.

Bull Case : ONC

The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 35.5% demonstrates continued momentum.

Bear Case : DRTS

The primary concerns for DRTS are Price/Book, Revenue Growth, EPS Growth.

Bear Case : ONC

The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 74.6x leaves little room for execution misses.

Key Dynamics to Monitor

DRTS profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.

DRTS carries more volatility with a beta of 1.17 — expect wider price swings.

ONC is growing revenue faster at 35.5% — sustainability is the question.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ONC scores higher overall (54/100 vs 17/100) and 35.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alpha Tau Medical Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha DaRT) for the treatment of solid cancer in Israel and the United States. The company is headquartered in Jerusalem, Israel.

Visit Website →

BeiGene, Ltd.

HEALTHCARE · BIOTECHNOLOGY · USA

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Want to dig deeper into these stocks?